CNSY.US Cerenome, Inc.

Healthcare Biotechnology USA Stocks
0.9502 USD
Close of Nov 14, 2026
0.4300 19.00
Market cap
USD 7.21M
P/E
-
P/B
1.31x
ROE
-584.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CNSY.US undervalued?

Graham number

The Graham number of Cerenome, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cerenome, Inc. fundamental analysis

No fundamental analysis for Cerenome, Inc. yet.

Cerenome, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cerenome, Inc.

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere…

Full company profile